HK1218749A1 - 取代的氧代吡啶衍生物及其在治療心血管病症方面的用途 - Google Patents

取代的氧代吡啶衍生物及其在治療心血管病症方面的用途

Info

Publication number: HK1218749A1
Authority: HK; Hong Kong
Prior art keywords: treatment; cardiovascular disorders; oxopyridine derivatives; substituted oxopyridine; substituted
Prior art date: 2013-03-28

Application number

HK16106721.5A

Other languages

English (en)

Inventor

Susanne Rhrig

Alexander Hillisch

Julia Straburger

Stefan Heitmeier

Martina Victoria Schmidt

Karl-Heinz Schlemmer

Adrian Tersteegen

Anja Buchmller

Christoph Gerdes

Martina Schfer

Tom Kinzel

Henrik Teller

Hartmut Schirok

Jrgen Klar

Nunez Eloisa Jimenez

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-28

Filing date

2016-06-13

Publication date

2017-03-10

2016-06-13 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2017-03-10 Publication of HK1218749A1 publication Critical patent/HK1218749A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Epidemiology (AREA)

HK16106721.5A 2013-03-28 2016-06-13 取代的氧代吡啶衍生物及其在治療心血管病症方面的用途 HK1218749A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP13161588		2013-03-28
EP13190944		2013-10-30
PCT/EP2014/056135 WO2014154794A1 (de)	2013-03-28	2014-03-27	Substituierte oxopyridin-derivate und ihre verwendung bei der behandlung von herz-kreislauf-erkrankungen

Publications (1)

Publication Number	Publication Date
HK1218749A1 true HK1218749A1 (zh)	2017-03-10

Family

ID=50390087

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16106721.5A HK1218749A1 (zh)	2013-03-28	2016-06-13	取代的氧代吡啶衍生物及其在治療心血管病症方面的用途

Country Status (26)

Country	Link
US (3)	US9434690B2 (zh)
EP (1)	EP2978756B1 (zh)
JP (2)	JP6266086B2 (zh)
KR (1)	KR20150137095A (zh)
CN (2)	CN108164513B (zh)
AP (1)	AP2015008782A0 (zh)
AU (1)	AU2014242971B2 (zh)
BR (1)	BR112015024414A2 (zh)
CA (1)	CA2908085C (zh)
CL (1)	CL2015002855A1 (zh)
CR (1)	CR20150476A (zh)
DO (1)	DOP2015000246A (zh)
EA (1)	EA028034B9 (zh)
ES (1)	ES2731819T3 (zh)
HK (1)	HK1218749A1 (zh)
MX (1)	MX2015013437A (zh)
NI (1)	NI201500143A (zh)
PE (1)	PE20151758A1 (zh)
PH (1)	PH12015502249A1 (zh)
SG (2)	SG10201710895UA (zh)
TN (1)	TN2015000434A1 (zh)
TW (1)	TWI633089B (zh)
UA (1)	UA115902C2 (zh)
UY (1)	UY35508A (zh)
WO (1)	WO2014154794A1 (zh)
ZA (1)	ZA201507155B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6479763B2 (ja)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
TWI633089B (zh) *	2013-03-28	2018-08-21	拜耳製藥股份有限公司	經取代的酮基吡啶衍生物
NO2760821T3 (zh)	2014-01-31	2018-03-10
KR102413453B1 (ko)	2014-01-31	2022-06-28	브리스톨-마이어스 스큅 컴퍼니	인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
WO2015120777A1 (zh) *	2014-02-14	2015-08-20	四川海思科制药有限公司	一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016036893A1 (en)	2014-09-04	2016-03-10	Bristol-Myers Squibb Company	Diamide macrocycles that are fxia inhibitors
WO2016046158A1 (de) *	2014-09-24	2016-03-31	Bayer Pharma Aktiengesellschaft	Substituierte oxopyridin-derivate
US10071995B2 (en)	2014-09-24	2018-09-11	Bayer Pharma Aktiengesellschaft	Substituted oxopyridine derivatives
US10414731B2 (en)	2014-09-24	2019-09-17	Bayer Pharma Aktiengesellschaft	Substituted oxopyridine derivatives
US10167280B2 (en)	2014-09-24	2019-01-01	Bayer Pharma Aktiengesellschaft	Substituted oxopyridine derivatives
WO2016046157A1 (de)	2014-09-24	2016-03-31	Bayer Pharma Aktiengesellschaft	Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
US9453018B2 (en)	2014-10-01	2016-09-27	Bristol-Myers Squibb Company	Pyrimidinones as factor XIa inhibitors
CN107428689A (zh) *	2015-03-19	2017-12-01	拜耳制药股份公司	作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
JO3703B1 (ar) *	2015-07-09	2021-01-31	Bayer Pharma AG	مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de)	2015-09-04	2018-07-11	Bayer Pharma Aktiengesellschaft	Substituierte oxopyridin-derivate
FR3046791B1 (fr) *	2016-01-18	2020-01-10	Adisseo France S.A.S.	Procede de preparation d'analogues de la methionine
US10633375B2 (en) *	2016-08-31	2020-04-28	Jinagsu Hengrui Medicine Co., Ltd	Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
CN110193012B (zh) *	2018-02-27	2022-02-08	江苏恒瑞医药股份有限公司	一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
AU2019227332A1 (en) *	2018-02-27	2020-08-27	Jiangsu Hengrui Medicine Co., Ltd.	Crystal form of oxopicolinamide derivative and preparation method therefor
LT3765452T (lt)	2018-03-15	2022-05-25	Bayer Aktiengesellschaft	Dviejų 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2- oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamido darinių gavimo būdas
KR20200141445A (ko)	2018-04-10	2020-12-18	바이엘 파마 악티엔게젤샤프트	치환된 옥소피리딘 유도체
AR117435A1 (es)	2018-12-21	2021-08-04	Bayer Ag	Derivados de oxopiridina sustituidos
WO2020127508A1 (en)	2018-12-21	2020-06-25	Bayer Aktiengesellschaft	Substituted oxopyridine derivatives
CN112047931B (zh) *	2019-06-06	2024-03-08	上海美悦生物科技发展有限公司	FXIa凝血因子抑制剂、其药物组合物和用途
CN112341377B (zh) *	2019-08-09	2024-05-14	上海美悦生物科技发展有限公司	一种杂环类化合物及其应用
GB201911816D0 (en) *	2019-08-16	2019-10-02	Univ London Queen Mary	Treatment
CN114206854B (zh) *	2019-09-27	2023-02-24	深圳信立泰药业股份有限公司	FXIa抑制剂及其制备方法和医药用途
CN112940431B (zh) *	2021-02-04	2023-03-10	四川大学	一种激光诱导的荧光发射组合物及图案化荧光发射方法
CN115108977A (zh) *	2021-03-19	2022-09-27	南京正大天晴制药有限公司	一种瑞戈非尼的制备方法
CN114920699B (zh) *	2022-05-31	2024-03-19	甘肃皓天科技股份有限公司	一种制备6-氯-2-甲基-2h-吲唑-5-胺的方法
CN116262740A (zh) *	2022-11-18	2023-06-16	成都施贝康生物医药科技有限公司	新型氧代吡啶类化合物及其制备方法和用途
CN116874469B (zh) *	2023-09-06	2023-11-10	成都施贝康生物医药科技有限公司	一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA005367B1 (ru) *	1999-05-19	2005-02-24	Фармация Корпорейшн	Замещенные пиридоны, их применение, композиция и способ ингибирования тромботических состояний и способы профилактики и лечения
PE20060285A1 (es) *	2004-03-30	2006-05-08	Aventis Pharma Inc	Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
US7361672B2 (en) *	2004-12-23	2008-04-22	Hoffmann-La Roche Inc.	Heteroarylacetamide inhibitors of factor Xa
NZ572418A (en) *	2006-05-05	2011-08-26	Millennium Pharm Inc	Factor xa inhibitors
EP2091947A2 (en) *	2006-12-20	2009-08-26	Takeda San Diego, Inc.	Glucokinase activators
WO2011077711A1 (ja) *	2009-12-22	2011-06-30	興和株式会社	新規な２－ピリドン誘導体及びこれを含有する医薬
NO2794597T3 (zh) *	2011-12-21	2018-04-14
BR112015002293A2 (pt) *	2012-08-03	2017-07-04	Bristol Myers Squibb Co	di-hidropiridona pi como inibidores do fator xia
WO2014160592A2 (en) *	2013-03-27	2014-10-02	Merck Sharp & Dohme Corp.	FACTOR XIa INHIBITORS
TWI633089B (zh) *	2013-03-28	2018-08-21	拜耳製藥股份有限公司	經取代的酮基吡啶衍生物

2014
- 2014-03-26 TW TW103111168A patent/TWI633089B/zh not_active IP Right Cessation
- 2014-03-27 EA EA201591874A patent/EA028034B9/ru not_active IP Right Cessation
- 2014-03-27 WO PCT/EP2014/056135 patent/WO2014154794A1/de active Application Filing
- 2014-03-27 MX MX2015013437A patent/MX2015013437A/es unknown
- 2014-03-27 BR BR112015024414A patent/BR112015024414A2/pt not_active Application Discontinuation
- 2014-03-27 UY UY0001035508A patent/UY35508A/es not_active Application Discontinuation
- 2014-03-27 CN CN201711458259.0A patent/CN108164513B/zh active Active
- 2014-03-27 US US14/780,925 patent/US9434690B2/en not_active Expired - Fee Related
- 2014-03-27 AP AP2015008782A patent/AP2015008782A0/xx unknown
- 2014-03-27 CA CA2908085A patent/CA2908085C/en active Active
- 2014-03-27 SG SG10201710895UA patent/SG10201710895UA/en unknown
- 2014-03-27 CN CN201480025730.5A patent/CN105164122B/zh active Active
- 2014-03-27 ES ES14713452T patent/ES2731819T3/es active Active
- 2014-03-27 PE PE2015002065A patent/PE20151758A1/es not_active Application Discontinuation
- 2014-03-27 SG SG11201506879RA patent/SG11201506879RA/en unknown
- 2014-03-27 KR KR1020157030938A patent/KR20150137095A/ko not_active Application Discontinuation
- 2014-03-27 AU AU2014242971A patent/AU2014242971B2/en not_active Ceased
- 2014-03-27 JP JP2016504671A patent/JP6266086B2/ja not_active Expired - Fee Related
- 2014-03-27 UA UAA201510454A patent/UA115902C2/uk unknown
- 2014-03-27 EP EP14713452.2A patent/EP2978756B1/de active Active
2015
- 2015-09-11 CR CR20150476A patent/CR20150476A/es unknown
- 2015-09-18 NI NI201500143A patent/NI201500143A/es unknown
- 2015-09-18 DO DO2015000246A patent/DOP2015000246A/es unknown
- 2015-09-22 TN TN2015000434A patent/TN2015000434A1/en unknown
- 2015-09-24 CL CL2015002855A patent/CL2015002855A1/es unknown
- 2015-09-24 PH PH12015502249A patent/PH12015502249A1/en unknown
- 2015-09-28 ZA ZA2015/07155A patent/ZA201507155B/en unknown
2016
- 2016-06-13 HK HK16106721.5A patent/HK1218749A1/zh not_active IP Right Cessation
- 2016-09-04 US US15/256,608 patent/US9822102B2/en active Active
2017
- 2017-10-17 US US15/786,352 patent/US10183932B2/en active Active
- 2017-12-19 JP JP2017242345A patent/JP6633045B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PH12015502249A1 (en)	2016-02-01
SG10201710895UA (en)	2018-02-27
AU2014242971B2 (en)	2018-07-05
KR20150137095A (ko)	2015-12-08
AU2014242971A1 (en)	2015-10-15
EP2978756B1 (de)	2019-03-27
JP6633045B2 (ja)	2020-01-22
AP2015008782A0 (en)	2015-10-31
CN108164513A (zh)	2018-06-15
CA2908085A1 (en)	2014-10-02
EA028034B9 (ru)	2018-02-28
UY35508A (es)	2014-10-31
PE20151758A1 (es)	2015-12-04
JP2018065856A (ja)	2018-04-26
EP2978756A1 (de)	2016-02-03
CN105164122B (zh)	2018-02-02
US20180086742A1 (en)	2018-03-29
EA201591874A1 (ru)	2016-04-29
MX2015013437A (es)	2016-05-18
SG11201506879RA (en)	2015-10-29
US9434690B2 (en)	2016-09-06
US10183932B2 (en)	2019-01-22
EA028034B1 (ru)	2017-09-29
JP2016515562A (ja)	2016-05-30
ES2731819T3 (es)	2019-11-19
US9822102B2 (en)	2017-11-21
CN108164513B (zh)	2021-05-07
CR20150476A (es)	2016-02-05
JP6266086B2 (ja)	2018-01-24
ZA201507155B (en)	2017-01-25
TW201524957A (zh)	2015-07-01
US20160052884A1 (en)	2016-02-25
BR112015024414A2 (pt)	2017-07-18
CA2908085C (en)	2021-12-28
TWI633089B (zh)	2018-08-21
UA115902C2 (uk)	2018-01-10
US20160368903A1 (en)	2016-12-22
NI201500143A (es)	2016-02-16
DOP2015000246A (es)	2015-11-15
CL2015002855A1 (es)	2016-08-26
CN105164122A (zh)	2015-12-16
WO2014154794A1 (de)	2014-10-02
TN2015000434A1 (en)	2017-01-03

Publication	Publication Date	Title
HK1218749A1 (zh)	2017-03-10	取代的氧代吡啶衍生物及其在治療心血管病症方面的用途
IL273688A (en)	2020-05-31	Evaluation and treatment of bradykinin-mediated disorders
HK1216251A1 (zh)	2016-10-28	吡唑並吡咯烷衍生物及其治病作用
HK1211497A1 (zh)	2016-05-27	在治療代謝障礙中使用的組合物和方法
EP2983657A4 (en)	2016-11-23	TREATMENT OF GASTROINTESTINAL AND OTHER DISEASES
PL3004108T3 (pl)	2018-03-30	Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
PL3004112T3 (pl)	2018-02-28	Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PL3466425T3 (pl)	2021-04-06	Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
HUE041418T2 (hu)	2019-05-28	Aromás vegyületek és alkalmazásuk csont metabolizmushoz kapcsolódó rendellenességek kezelésére
HK1209033A1 (zh)	2016-06-30	奧地帕西在治療黏多醣症病中的應用
AP2015008849A0 (en)	2015-11-30	Pyrazolopyrrolidine derivatives and their use in the treatment of disease
HUE047636T2 (hu)	2020-05-28	Arginin csontízületi gyulladás kezelésében és/vagy megelõzésében történõ alkalmazásra

Legal Events

Date	Code	Title	Description
2022-10-21	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20220324